Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Enterprise Value (2016 - 2025)

Historic Enterprise Value for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to -$2.8 billion.

  • United Therapeutics' Enterprise Value rose 1680.14% to -$2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.8 billion, marking a year-over-year increase of 1680.14%. This contributed to the annual value of -$3.3 billion for FY2024, which is 911.46% down from last year.
  • Per United Therapeutics' latest filing, its Enterprise Value stood at -$2.8 billion for Q3 2025, which was up 1680.14% from -$3.0 billion recorded in Q2 2025.
  • United Therapeutics' Enterprise Value's 5-year high stood at -$1.7 billion during Q1 2021, with a 5-year trough of -$3.3 billion in Q3 2024.
  • For the 5-year period, United Therapeutics' Enterprise Value averaged around -$2.7 billion, with its median value being -$2.8 billion (2025).
  • Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 4702.96% in 2022, then skyrocketed by 1680.14% in 2025.
  • United Therapeutics' Enterprise Value (Quarter) stood at -$1.9 billion in 2021, then plummeted by 47.03% to -$2.8 billion in 2022, then dropped by 5.47% to -$3.0 billion in 2023, then decreased by 9.11% to -$3.3 billion in 2024, then grew by 15.29% to -$2.8 billion in 2025.
  • Its Enterprise Value was -$2.8 billion in Q3 2025, compared to -$3.0 billion in Q2 2025 and -$3.3 billion in Q1 2025.